Equity Research Coverage Reports

Hexagon Resources Limited (ASX: HXG) - Premium Graphite - Key Qualities Required for Premium Products like Battery
Sunday, January 28, 2018
We have completed a valuation for Hexagon, with this resulting in a base case risked Company valuation of A$156 million, or A$0.37/share, diluted for a conceptual funding model for McIntosh. The aim is to develop the Project as a long term, reliable supplier of a range of premium graphite products with consistent quality, and differentiate itself from competitors.
Download Report
Calima Energy Limited (ASX:CE1) - Drilling of Three Horizontal Wells - Liquids-Rich Areas of The Montney - British Columbia, Canada
Sunday, October 22, 2017
We have a base case 6-month price target of A$0.15/share for Calima, based on a land value of C$2,500/acre, and a fully diluted structure including the current fully diluted share base plus 200 million shares issued through upcoming capital raisings of a minimum of A$20 million at $0.10/share to fund the farm-in drilling.
Download Report
Oneall International Limited (ASX: 1AL) - Outdoor Furniture - Sold in 42 Countries - Acquisition - Strong Balance Sheet & Growth Prospects
Thursday, October 19, 2017
Revenue increased 14.4% on the pcp to $25.9m and the NPAT increased 13.0% to $5.7m. Revenue growth was realised from improved sales volumes.
Download Report
Chatham Rock Phosphate (TSXV:NZP, NZAX:CRP, FSE:3GRE) - Low Capex, High Quality Phosphate
Tuesday, October 17, 2017
We have completed a risked DCF valuation for CRP, with the tabular form presented in our report. This is a base case valuation, with significant upside on de-risking, particularly with grant of the Marine Consents. The per share valuation is based on the current share structure diluted for raisings of US$14.14 million as flagged by the Company.
Download Report
Sienna Cancer Diagnostics Limited (ASX: SDX) - IVD Test for Bladder Cancer - Distribution Agreements in the US & Europe
Monday, October 9, 2017
We have determined a base case valuation for SDX of $0.31 per share. The valuation incorporates a number of assumptions regarding the sales of the IVD product for the detection of bladder cancer in the US and Europe. The product has been de-risked to a large extent given the company has obtained an IVD classification in the US, Europe and Australia.
Download Report